Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cypher class action suit?

This article was originally published in The Gray Sheet

Executive Summary

Kenneth B. Moll & Associates will decide by year-end whether to pursue a class action suit against Johnson & Johnson/Cordis for deaths related to implantation of its sirolimus-eluting stent. Moll currently is conducting an investigation of Cypher patient data FDA released in October that estimated a 0.01% worldwide mortality rate for the device (1"The Gray Sheet" Nov. 3, 2003, p. 4). In June, the Chicago law firm brought a class action suit against Guidant because of deaths related to its Ancure AAA system; the suit is currently in discovery...

You may also be interested in...

Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February

FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts